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In this study the syntheses of 11 novel lignans are described. Their cytotoxicities are studied in 
GLC4, a human small cell lung carcinoma cell line, using the microculture tetrazolium (MTT) 
assay. Ten of these compounds were substituted with a menthyloxy group on the 5-position of the 
lactone. These compounds can easily be prepared in (novel) ‘one-pot’, three- or four-step 
syntheses. In addition, methods for controlling the stereogenic centers are described. 
Furthermore, five naturally occurring podophyllotoxin-related compounds were tested. The 
cytotoxicities of all lignan compounds, and of three non-lignan intermediates originating from the 
syntheses, were compared with the clinically applied anticancer agents etoposide, teniposide, and 
cisplatin. Most compounds showed moderate to high activities against GLC4, and two of the 
compounds containing a menthyloxy group showed activities comparable to the reference 
cytotoxic agents. 
Introduction 
Lignans form an important class of compounds that are 
being applied in cancer chemotherapy. There is a 
demonstrated need of novel anticancer agents, and these 
can be found among lignan-related structures. These 
compounds can be investigated either by isolating lignans 
from plant material, which can be followed by 
(semisynthetic) derivatization, or by total synthesis. In 
this study the structure-activity relationships (SAR) 
among a range of naturally occurring lignans,1 syntheti-
cally prepared lignans,2 intermediates from these syn-
theses, and semisynthetic derivatives obtained from 
naturally occurring lignans have been investigated.3 The 
compounds for SAR-investigation (Table 1) were divided 
into four groups in which structural elements were 
altered, (a) removal or addition of the benzyl-, ethoxy-
ethyl-, 1,3-propyldithiane-, thiophenyl-, and methylene-
dioxy-protective groups, (b) removal or alteration of the 
menthyloxy group, (c) podophyllotoxin-like compounds, 
and (d) non-lignan compounds synthesized for assign-
ment of the stereogenic centers of the lignan compounds. 
The cytotoxicity of these compounds was evaluated in 
GLC4,4 a human small cell lung carcinoma cell line, 
using the microculture tetrazolium (MTT) assay.5 The 
GLC4 cell line was used because etoposide (VP-16-213) 
and teniposide (VM-26), two clinically applied anti-
cancer agents that are semisynthetic derivatives of 
podophyllotoxin,6 are known to be particularly active 
against small cell lung tumors. These two compounds 
induce double-stranded DNA breaks by inhibiting the 
topoisomerase II repair system. In contrast, podophyllo-
toxin and deoxypodophyllotoxin are known to act as 
antimitotic spindle poisons. By binding to tubulin, these 
compounds inhibit microtubule formation. 
The total syntheses of 5-methoxypodophyllotoxin (1), 
(-)-pluviatolide2  (2),  and  (-)-hinokinin2  (3)   (Figure  1) 
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5-methoxypodophyllotoxin (-)-pluviatolide (-)-hinokinin 
Figure 1.  Three naturally occurring lignans obtained via total
syntheses. 
yielded several lignans and lignan intermediates which 
are based structurally on l-menthol. These compounds are 
biologically interesting because a large menthyloxy 
group might block the binding to tubulin. Our first aim 
was to study whether the compounds containing a 
menthyloxy group at the lactone segment might exhibit 
promising cytotoxic activity. In addition, to enlarge the 
scope of this study, other related podophyllotoxin-like 
compounds were isolated from Podophyllum hexandrum 
Royle and Linum flavum L.1 or synthesized from podo-
phyllotoxin.3 As reference compounds the clinically 
applied anticancer agents etoposide, teniposide, and 
cisplatin were used. 
Chemistry 
A Michael addition in dry tetrahydrofuran (THF), using 
(5R)-(l-menthyloxy)-2(5H)-furanone (5) as a Michael 
acceptor and freshly prepared lithiated dithianes 4 as 
Michael donors, yielded lithium enolate 6 (Scheme 1). 
Lignans could then be obtained in two different ways. 
Quenching this enolate with the appropriate benzylic 
bromides yielded the lignan compounds 7-92 under 
conditions providing total control of all stereogenic 
centers. Reaction of the enolate formed after a Michael 
addition with the appropriate benzaldehydes yielded the 
lignan compounds 10 and 11. The desired stereochem-
istry  at  the  hydroxyl  functionality  formed   during   the 
0022-2623/95/1838-2112$09.00/0 © 1995 American Chemical Society 
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Scheme 1a 
a (a) -78 °C, THF; (b) ArCH2Br; (c) (1) ethylene chloroboronate, -50 °C or chlorotitanium tris(diethylamide), -45 °C, (2) ArCHO, 
-110 to -100 °C, (3) NH4F; (d) HgCl2/CaCO3, CH3CN/H2O, 20°C; (e) vinyl ethyl ether/H+, THF, -12°C. 
aldol condensation was achieved by transmetalation of 
the lithium enolate 6 to the boron7 or titanium8 enolates 
(Scheme 1). Using this method, one of the π-faces is 
effectively shielded so that only the syn-product can be 
formed in the condensation reaction with an aldehyde. 
In the synthesis of compound 11, compound 12 (Table 
1) was isolated as a side product (11%). 
Hydrolysis of the thioketal functionality in compound 
10 was accomplished using mercury(II) chloride in 
aqueous acetonitrile;9 compound 13 was obtained. Pro-
tection of the C6-hydroxyl functionality of compounds 
10 and 13 with an ethoxyethyl group provided com-
pounds 14 and 15, respectively. Protection was ac-
complished by reaction with vinyl ethyl ether and a 
catalytic amount of toluene sulfonic acid in dry toluene. 
Reduction of the thioketal in compound 9 was per-
formed with Raney nickel2a in THF, to provide com-
pound 16. Reduction of the thioketal in compound 8 was 
performed in methanol with ‘Ni2B’ generated in situ 
from NiCl2 and NaBH4. Removal of the benzyl-protec-
tive group provided compound 2. The reduction of the 
ketal moiety in compound 8, with removal of the chiral 
auxiliary, was accomplished by adding aqueous potas-
sium hydroxide and sodium borohydride to this reaction 
mixture. After acidic workup and subsequent depro-
tection of the 4´-hydroxyl functionality using palladium-
black under a hydrogen atmosphere, (-)-pluviatolide (2) 
was obtained.2b 
(5R)-(l-Menthyloxy)-2(5H)-furanone (5) was also 
used for the synthesis of (-)-hinokinin (3). An analogous 
procedure using 5-methoxy-2(5H)-furanone yielded 
compound 18.2b 
The total syntheses yielded several other lactones 
(24-26; Table 1). Using the same procedures as those 
used for the Michael additions in the previously de-
scribed lignan syntheses, the enolate anion 6 was 
quenched with an aqueous ammonium chloride solution 
to give the monobenzylated furanone. These compounds 
enabled us to prove the antiselectivity of the Michael 
additions   by   two-dimensional   1H  NMR,   the   trans- 
relationship between the substituents at C4 and C5 of 
the lactone could easily be determined by the small 
coupling constant (J < 2 Hz). The trans-stereochemistry 
at the C3 stereocenter at the lactone ring was easily 
deduced from 1H NMR and, in one case, confirmed by 
X-ray analysis as described previously.2c Assignment of 
the stereochemistry of the fourth exocyclic stereogenic 
center, which was formed during the aldol condensation, 
was more difficult because no NOE effect was observed 
in two-dimensional NMR for this proton; this is consis-
tent with the stereochemistry indicated, but it is not 
absolute proof. For crystalline compounds, the stereo-
chemistry of this stereogenic center can be assigned 
unambiguously, using X-ray crystallography, as de-
scribed by Jansen.2c 
Deoxypodophyllotoxin (23) was synthesized from podo-
phyllotoxin (20) by using palladium-black in acetic acid3 
under a hydrogen atmosphere. 5-Methoxypodophyllo-
toxin (1) was isolated from cell cultures of L. flavum L.1 
(Linaceae), and 4´-demethylpodophyllotoxin (21) was 
isolated from cell cultures of P. hexandrum Royle3 
(Berberidaceae). Podophyllotoxin glucoside (19) was 
synthesized following procedures that have been de-
scribed for the syntheses of etoposide and teniposide.6 
The compounds described above are summarized in 
Table 1. 
Biological Results 
Biological results are listed in Table 2. For the 
structural formulas, see Table 1. Comparing the cyto-
toxic effects of compounds within the structural groups 
a-d (see Introduction), based on continuous as well as 
2 h incubation, some general effects were observed with 
respect to the chemical structures and their substituents. 
These are summarized below. 
R1.  Removal of the methylenedioxy group of com-
pound 11 to give 12, resulting in two free hydroxyl 
groups, significantly enhanced the activity following 
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Table 1.  Compounds Used for Cytotoxicity Testsa 
(a) Removal and Addition of Protective Groups 
 R1 R1' R2 R3 R4 
10 -CH2- S(CH2)3S H CH3 
11 -CH2- S(CH2)3S H Bn 
12 H H S(CH2)3S H Bn 
13 -CH2- O H CH3 
14 -CH2- S(CH2)3S EE CH3 
15 -CH2- O EE CH3 
(b) Addition and Removal of Protective Groups;
Alteration or Removal of the Menthyloxy Group 
 R1 R1' R2 R4 R5 R6 
2 -CH2- H H CH3 H 
7 CH3 CH3 H CH3 CH3 OM* 
8 -CH2- SPh Bn CH3 OM* 
9 -CH2- SPh -CH2- OM* 
16 -CH2- H -CH2- OM* 
18 -CH2- SPh -CH2- OCH3 
(c) Podophyllotoxin-like Compounds 
 R2 R4 R7 
1 OH CH3 OCH3 
19 OGlu CH3 H 
20 OH CH3 H 
21 OH H H 
23 H CH3 H 
(d) Removal of the Menthyloxy Group 
 R6 R7 
24 OM* OCH3 
25 H OCH3 
26 H H 
a EE = ethoxyethyl, Br = benzyl, M* = l-menthyl, Glu = 
glucoside. 
duced instead of a methylenedioxy group (7 versus 16), 
no significant difference in cytotoxicity was observed. 
R2.  Compounds with a carbonyl functionality at C7 
showed the highest cytotoxicity (13, 15). Replacing a 
carbonyl by a dithiane reduced the activity against 
GLC4  (p  <  0.05,  13  versus  10  and   15   versus   14). 
Table 2.  Cytotoxic Effects of the Test Compounds against 
GLC4; IC50 Mean Values ± SD (n = 3) (µM) 
compd continuous incubation 2 h incubationa 
7 35 ± 4 not tested 
8 >100 not tested 
9 40 ± 3 not tested 
10 8.8 ± 1.5 75 ± 9 
11 48 ± 3 not tested 
12 10 ± 2 > 100 
13 1.7 ± 0.3 7.2 ± 0.7 
14 10 ± 2 33 ± 4 
15 0.83 ± 0.07 2.0 ± 0.2 
16 44 ± 5 not tested 
2 6.5 ± 0.8 >100 
18 >100 not tested 
19 10 ± 2 58 ± 6 
20 0.06 ± 0.01 0.15 ± 0.04 
21 0.03 ± 0.01 3.1 ± 0.2 
1 (= 22) 0.06 ± 0.01 0.25 ± 0.04 
23 0.008 ± 0.001 0.12 ± 0.02 
24 29 ± 4 not tested 
25 54 ± 7 not tested 
26 36 ± 4 not tested 
etoposide 0.82 ± 0.04 4.0 ± 0.4 
teniposide 0.48 ± 0.02 2.8 ± 0.2 
cisplatin 1.1 ± 0.2 4.6 ± 0.2 
a Compounds showing an IC50 value exceeding 10 µM in
continuous incubations were not tested in 2 h incubations. 
Further enlargement of the dithiane moiety reduced
activity (compare Table 1, parts a and b). Cytotoxic
effects comparable to etoposide, teniposide, and cisplatin
were observed for compounds 13 and 15. Comparing
these results with Table 1c of the podophyllotoxin-like
compounds, a free hydroxyl group at C7 and ring closure
further enhanced the activity (20-22). Converting
podophyllotoxin (20) to deoxypodophyllotoxin (23) even
provided a stronger cytotoxicity. Glycosilation of the
hydroxyl group (20) with a glucose moiety (19) strongly
reduced the activity. 
R3.  How a free hydroxyl group at the benzylic
position (10-13) influences cytotoxicity cannot be con-
cluded from our experiments. On the other hand,
protecting the hydroxyl functionality with an ethoxy-
ethyl group significantly enhanced the activity found in
2 h incubations (compare 10 to 14 and 13 to 15).
Following continuous incubation, however, this effect
was less pronounced or even absent. Ring-closed podo-
phyllotoxin-like structures (20-23) showed the highest
cytotoxic effects (Table 1c). 
R4.  Compared to a methoxy group, a benzyl group at
R4 reduced the activity (p < 0.05, 10 compared to 11).
Within the range of podophyllotoxin-like compounds
(20 and 21), a free hydroxyl compared to a methoxy sub-
stituent at C4´ (Figure 1), significantly reduced the
activity after a 2 h incubation period. In continuous
incubation it slightly enhanced the activity. 
R5.  Introduction of a methylenedioxy functionality
instead of a methoxy substituent did not lead to
significant differences in cytotoxicity. Compounds 7 and
16 showed similar activities. 
R6.  A compound containing a methoxy group showed
a much higher IC50 value than one with a menthyloxy
group (p < 0.05, 18 versus 9), indicating that a men-
thyloxy group at this position could enhance the activity.
From our experiments the possible effects of removing
the menthyl group cannot be deduced. 
R7.  A methoxy substituent at R7 did not significantly
influence the  activity  (25  versus  26).  Podophyllotoxin 
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Table 3.  Evaluation of the General Structure-Activity 
Relationships of the Tested Compounds 
structural  
group structural elements 
a (Table 1a,b) R1 = CH3 « CH2 < H 
 R2 = SPh < S(CH2)3S < H < O 
 R3 = H < OH < OEE < ring-closed structure 
 R4 = Bn < CH3 < H 
b (Table 1c,d) R6 = OCH3 < OM* 
c (Table 1c) R2 = OGlu « OH ~ H 
 R4 = H < CH3 
 R7 = H ~ OCH3 
(20) and 5-methoxypodophyllotoxin (1) showed compa-
rable cytotoxicities. 
The results of this study are summarized in the Table 
3 in which the structural elements are arranged in order 
of their influence on the activities. 
Discussion 
Compounds 10 and 11 were synthesized in a novel,2 
‘one-pot’ four-step synthesis. These kinds of compounds 
would normally be prepared step by step. The large 
advantage of this approach is that these compounds can 
now readily be synthesized within 1 day, with total 
control of all stereogenic centers. Purification steps take 
less time because all starting materials can now easily be 
removed by flash chromatography, and purification of 
the products can be carried out by column chroma-
tography. Synthesizing these compounds step by step 
can imply a number of purification steps, which in some 
cases can be a real problem as described in this paper for 
compound 25. 
From Table 2 it can be seen that for several com-
pounds (2, 10, 12, 21) a very large difference in cyto-
toxicity was found between 2 h and continuous incuba-
tion. These differences may be explained in terms of the 
structure of these compounds. Probably the substituents 
are too bulky, or possess a low-lipophilic character, 
resulting in low intracellular concentration after 2 h 
exposure. Increasing cytotoxicity has been found with 
increasing lipophilicity.10 The difference in cytotoxicity 
(continuous incubation) between a compound with a 
methoxy group and compounds with a menthyloxy 
group (9 versus 18) could also be explained in terms of 
different lipophilicities. The benzyl substituent in 
compounds 8 and 11 seems to be too bulky; although 
these compounds possess a more lipophilic character, 
their cytotoxic effect is reduced compared to compounds 
with a methoxy substituent at this position (10, 13-15). 
The more bulky phenyldithianes (8, 9, 18) showed lower 
cytotoxic effects compared to the less bulky 
propyldithianes (10-12, 14). 
From our study it may be concluded that some 
structural elements influence the cytotoxicity. An 
ethoxyethyl group (14, 15 compared to 10, 13), a 
carbonyl (13, 15 compared to 10, 14), a free hydroxyl 
(12, 16), and ring closure (20-23) enhanced cytotoxicity 
within our range of lignan compounds. A benzyl-
protective group (11, 15) and dithiane-protective groups 
(10, 14, 18 versus 13, 15, 2) seemed to reduce the 
cytotoxic effects. 
On the basis of IC50 values, deoxypodophyllotoxin (23) 
was about 8 times more toxic than podophyllotoxin (20) 
in continuous incubations, in contrast to the difference 
of a factor of only 2 times found in 2 h incubations. The 
difference in biological activity as found in our  study  is 
not in agreement with earlier SAR studies carried out 
with podophyllotoxin,11 in which it was concluded that 
the free hydroxyl at C7 is partially responsible for the 
binding to tubulin. Both compounds are known to act as 
antimitotic spindle poisons. 
Compounds 13 and 15 showed activities to GLC4 in 
the same range as etoposide, teniposide, and cisplatin. 
Whether their cytotoxicity is a result of binding to the 
enzyme topoisomerase II, which is essential in the DNA 
breakage-reunion process, or whether they act as 
spindle poisons by binding to tubulin is not clear from 
our experiments. Further studies should reveal whether 
one of the substituents (for instance a menthyloxy 
group) is able to block the binding to tubulin. Com-
pounds 13 and 15 are the most interesting of the 
synthesized compounds based upon their IC50 values. 
Experimental Section 
Cell Line.  GLC4, a human small cell lung carcinoma cell
line, was derived from a pleural effusion at the Department of
Internal Medicine, University Hospital Groningen, The
Netherlands.4 This cell line grows in suspension culture, partly
floating and partly attached, in RPMI 1640 medium (Gibco,
Paisly, U.K.), supplemented with 10% heat-inactivated (30
min, 56 °C) fetal calf serum (Gibco) plus 50 µg/mL
streptomycin and 50 IU/mL penicillin. It was maintained at 37
°C in a humidified atmosphere with 5% CO2. The doubling
time was 18-21 h. Cells were in the exponential phase of
growth at the moment of testing the compounds. The viability
of the cells used in the experiments exceeded 90% as deter-
mined with trypan blue. 
Cytotoxicity Assay.  Cytotoxicity after treatment of the
tumor cells with the test compounds was determined using the
microculture tetrazolium (MTT) assay.5 This assay is based on
the reduction of a soluble tetrazolium salt by mitochondrial
dehydrogenase activity of viable tumor cells to an insoluble,
colored formazan product. 
The amount of this formazan product can be measured
spectrophotometrically after dissolution10 in dimethyl sulfoxide
(Merck, Darmstadt, FRG). Under the experimental conditions
used in the present study, the enzyme activity and the amount
of formazan formed were proportional to the amount of cells.
Reduction in the amount of cells by a particular agent can
generally be explained by killing of cells and/or inhibition of
cell proliferation. 
Concentrated stock solutions (200 × ) were made in dimethyl
sulfoxide and stored at -20 °C. Exponentially growing cells
were harvested. The cell suspension was diluted appropriately
with RPMI 1640 medium plus 10% fetal calf serum. Of this
cell suspension, 50 µL containing 3750 cells was pipetted into
96-well micro titer plates (Nunc, Roskilde, DK). 
Subsequently, 50 µL of a solution of the test compounds,
obtained by diluting the stocks with RPMI 1640 medium plus
10% fetal calf serum, was added to each well. The small
amount of dimethyl sulfoxide present in the wells (maximum
0.25%) proved not to affect the experiments. The highest
concentration of the compounds tested was 100 µM. 
The cells were exposed to the test compounds either
continuously (4 days) or for 2 h. Only compounds with an IC50≤ 10 µM following continuous exposure were used for the 2 h
incubations. After the 2 h exposure period at 37 °C in a
humidified atmosphere with 5% CO2, the cells were washed
three times with 200 µL of culture medium (10 min, 20 °C,
210g). After the washing steps, the plates were incubated in the
same atmosphere for a culture period of 4 days. 
A 5 mg/mL solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma, St, Louis, MO) was
prepared in phosphate-buffered saline (PBS; 1.5 mM KH2PO4,
6.5 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl; pH 7.4). Of
this solution, 20 µL was pipetted into each well. Following
an incubation  time  of  3 h 45 min  with  MTT  at  37  °C  in  a 
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humidified atmosphere with 5% CO2 and centrifugation of the 
plates (15 min, 20 °C, 210g), the medium was carefully 
aspirated. 
The formazan product formed was then dissolved in 200 µL 
of dimethyl sulfoxide. After thorough mixing, the absorbance 
was measured at 520 nm using a scanning microtiterwell 
spectrophotometer (Titertek Multiscan; Flow Laboratories, 
Irvine, U.K.). 
Cell growth inhibition (or killing) was calculated using the 
formula: growth inhibition (%) = [1 - [(absorbance of treated 
cells - absorbance of culture medium)/ (absorbance of un-
treated cells - absorbance of culture medium)]] × 100. The IC50 
value (the concentration of test compound causing 50% growth 
inhibition of the tumor cells) was used as a parameter for 
cytotoxicity. 
Statistics.  For comparison of the results of the experiments, 
the Student’s t-test was used. A p-value <0.05 was considered 
significant. All experiments were carried out in triplicate 
(separate experiments). 
Chemistry. 1H-NMR spectra were recorded on a Varian XL-
200 (200 MHz), Varian XR-300S (300 MHz), or Bruker AMX 
400 wb instrument. 13C-NMR spectra were recorded on Nicolet 
NT 200 (50.32 MHz) and Varian 300 VXR 300S (75.48 MHz) 
spectrometers. The chemical shifts are given in δ units (ppm) 
relative to TMS (δ = 0 ppm), and signal multiplicity was 
designated according to the following abbreviations: s, singlet; 
d, doublet; t, triplet; q, quartet; br, broad singlet; m, multiplet. 
HRMS spectra were recorded on a AEI MS-902 spectrometer 
(EI). Melting points were determined on a Mettler FP-2 
(uncorrected). Optical rotations were measured at the Na D-line 
on a Perkin Elmer 241 MC instrument at room temperature. 
Chloroform was used as a solvent. Chromatography was 
performed using silica gel 60 F254 (Merck, Art. No. 7734 or 
9385). Rf values were determined on TLC plates precoated with 
0.25 mm thick silica gel 60 F254 (Merck Art. No. 5714). Unless 
otherwise noted, Rf = 0.3 for compounds purified by 
chromatography. Solvents were purified using standard 
procedures. (5R)-(l-Menthyloxy)-2(5H)-furanone (5) was 
synthesized according to a procedure previously described by 
de Jong and Feringa.12 2-Methoxy-3,4-(methylenedioxy)-
benzaldehyde was synthesized according to a procedure de-
scribed by Baker et al.13 Chlorotitanium tris(diethylamide) was 
freshly prepared as described by Reetz and Urz.8 Ethylene 
chloroboronate was synthesized following a procedure 
described Hoffmann and Dittrich.14 3,4,5-Trimethoxybenz-
aldehyde, podophyllotoxin, and syringaldehyde were purchased 
from Janssen Chimica (Beerse, Belgium). Compound 20 was 
synthesized according to a procedure described in the litera-
ture.15 Syringaldehyde was benzylated using a procedure 
described by Loirot et al.16 The syntheses of compounds 7-9 
and 16-18 have been described elsewhere (protocols and 
analyses).2 Isolation procedures for compounds 20-22 also 
have been described elsewhere.1 Reactions that were sensitive 
to air and moisture were carried out under nitrogen atmosphere 
using flame-dried glassware. 
1,2-(Methylenedioxy)-3-methoxy-4-[(1,3-propylenedi-
thio)methyl]benzene (4).  To a solution of 2-methoxy-3,4-
(methylenedioxy)benzaldehyde (12 g, 80 mmol) in toluene (80 
mL) were added 1,3-propanedithiol (6.1 g, 80 mmol) and 
toluenesulfonic acid (0.1 g, catalytic amount). The reaction was 
carried out overnight with azeotropic removal of water. The 
solvent was removed in vacuo and the residue redissolved in 
chloroform (50 mL). The organic layer was washed with water 
(100 mL) subsequently and twice with 1 N NaOH and dried 
over magnesium sulfate. Removal of the solvent under reduced 
presure yielded a yellowish colored oil, which was 
recrystallized from THF-hexane to provide colorless cubic 
crystals of the pure 1,3-propyldithiane of 2-methoxy-3,4-
(methylenedioxy)benzaldehyde (4) (17.5 g, 81%): mp 155 °C; 
1H NMR (CDCl3) δ 6.82 (dd, 2 H, JAB = 18.2 Hz, Ar-H), 5.92 
(s, 2 H, OCH2O), 5.56 (s, 1 H, (SR)2C-H), 4.05 (s, 3 H, OCH3), 
2.83-3.19 (m, 4 H, SCH2), 1.76-2.14 (m, 2 H, CH2);13C NMR 
(CDCl3) δ 149.1 (s), 140.1 (s), 136.2 (s), 124.6 (d), 122.2 (d), 
103.3 (t), 101.1 (d), 60.2 (q), 43.7 (d), 32.5 (t), 25.3 (t); HRMS 
270.038,  calcd for C12H14O5S2 270.038;  MS (rel intensity) 272 
(M+, 10), 271 (15), 270 (100), 197 (12), 196 (69), 195 (14), 167 
(14), 165 (19), 163 (17). 
General Procedure for the Formation of the Enolate; 
Michael Addition of Lithiated 4 to (5R)-(l-Menthyloxy)-
2(5H)-furanone (5) (Table 1a).  To a solution of 4 (1.12 g, 
4.16 mmol) in dry THF (40 mL) at -78 °C was added n-BuLi 
(2.00 mL, 2.5 M, in hexane, 5 mmol) dropwise within a period 
of 30 min. Stirring was continued for 30 min, and then a 
solution of (5R)-(l-menthyloxy)-2(5H)-furanone (5) (1.00 g, 
4.58 mmol) in THF (5 mL) was added dropwise over a period 
of 20 min at -90 °C. The orange-brown lithium enolate solution 
of 6 was used as such in further syntheses. 
General Procedure for Transmetalation to the Titanium 
and Boron Enolates (Table 1a).  At -90 °C chlorotitanium 
tris(diethylamide)8 (4.0 mL, 12.6 mmol) was added to the 
lithium enolate solution. The temperature was allowed to rise to 
-45 °C over a period of 40 min, resulting in the formation of the 
dark red titanium enolate solution. This solution was used as 
such in further syntheses. 
At -50 °C ethylene chloroboronate (1.0 g, 9.4 mmol) was 
added to the lithium enolate solution. The temperature was 
allowed to rise to -15 °C over a period of 1 h; this resulted in 




2(3H)-furanone (10).  To the titanium (at -110 °C) or boron 
enolate solution (at -100 °C) was added a solution of 3,4,5-
trimethoxybenzaldehyde (0.88 g, 4.56 mmol) in THF (5 mL) 
dropwise over a period of 2 h. The reaction mixture was poured 
into a concentrated aqueous ammonium fluoride solution (ca. 
200 mL) and extracted with diethyl ether (2 × 100 mL). The 
organic layer was washed with water (50 mL) and brine (50 
mL) and dried over anhydrous sodium sulfate. Removal of the 
solvent yielded a brown-red oil that was submitted to flash 
chromatography with dichloromethane as eluent (Rf 10 = 0), to 
remove some starting material. Then diethyl ether was used as 
eluent to give the crude product mixture. Column 
chromatography (diethyl ether/hexane, 3:2) yielded compound 
10, 1.55 g (2.2 mmol, 53%), as a white foam that became a 
slightly yellow oil upon standing: [α]D -10.2° (c = 1); 1H NMR 
(CDCl3) δ 0.65-1.5 (m, 16 H, menthyl), 1.7-2.3 (m, 4 H, CH-
menthyl and CH2-dithiane), 2.4-2.8 (m, 5 H, SCH2 and C8-H), 
2.9-3.1 (m, 1 H, OCH-menthyl), 3.3-3.35 (br, 1 H, C8´-H or 
OH), 3.64 (s, 6 H, OCH3), 3.75 (s, 3 H, OCH3), 3.8 (br, 1 H, Ar-
CHOR), 4.05 (s, 3 H, OCH3), 4.65-4.8 (br, 1 H, CH-Omenthyl), 
5.99 (d, 2 H, 2J = 7 Hz, OCH2O), 6.25 (s, 2 H, Ar-H), 6.41 (d, 1 
H, 3JAB = 8.5 Hz, Ar-H), 7.08 (d, 1 H, 3JAB = 8.5 Hz); 13C NMR 
(CDCl3) δ 14.1 (d), 15.5 (q), 21.0 (q), 22.1 (d), 22.8 (t), 24.0 (t), 
25.7 (q), 26.9 (t), 27.6 (t), 31.2 (d), 31.5 (t), 34.2 (t), 39.5 (t), 
47.6 (q), 52.5 (d), 55.7 (d), 59.0 (q), 60.6 (s), 60.7 (q), 75.2 (d), 
78.2 (d), 101.1 (d), 101.5 (t), 102.1 (d), 124.7 (d), 135.0 (s), 
137.4 (s), 139.4 (s), 142.1 (s), 143.0 (s), 149.6 (s), 152.7 (s), 
178.4 (s); HRMS 704.763, calcd for C36H47O10S2 704.763; MS 
(rel intensity) 704 (M+, 0.36), 508 (6), 360 (4), 324 (4), 296 (6), 
269 (75), 250 (19), 196 (39), 195 (27), 181 (15), 165 (12), 83 




thyloxy)dihydro-2(3H)-furanone (11).  The same procedure 
was used as described above for 10 except that 4-(benzyloxy)-
3,5-dimethoxybenzaldehyde was used instead of the 3,4,5-
trimethoxybenzaldehyde. In the final column chromatogra-
phy,  diethyl ether/hexane (2:1) was used as the eluent. 
Compound 11, 1.71 g (2.2 mmol, 53%), was obtained as a 
white solid, which became an oil upon standing: [α]D -12.5° (c 
= 1); 1H NMR (CDCl3) δ 0.6-1.4 (m, 16 H, menthyl), 1.4-2.0 
(m, 4 H, CH-menthyl and CH2-dithiane), 2.0-2.2 (br, 1 H, C8-
H), 2.2-3.0 (m, 4 H, SCH2), 3.25-3.3 (br, 1 H, OCH-menthyl), 
3.3-3.6 (m, 1 H, C8´-H), 3.62 (s, 3 H, OCH3), 3.82 (s, 6 H, 
OCH3), 3.88 (s, 3 H, OCH3), 3.9-4.0 (br, 1 H, ArCHOHR), 
4.65-4.85 (br, 1 H, OCH-Omenthyl), 5.00 (s, 2 H, OCH2Ph), 
5.96 (d, 2 H, 3J = 10.3 Hz, OCH2O), 6.52 (d, 1 H, 3JAB = 8.3 
Hz, Ar-H), 6.53 (s, 1 H, Ar-H), 6.53 (s, 1 H, Ar-H), 7.36 (d, 1 
H, 3JAB = 8.3 Hz, Ar-H),  7.3-7.4  (m, 3 H, Ar-H),  7.50  (d, 2 H, 
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3J = 6.8 Hz, Ar-H); 13C NMR (CDCl3) δ 15.4 (d), 15.5 (q), 20.9 
(q), 22.0 (d), 22.8 (t), 24.0 (t), 25.7 (q) 26.9 (t), 28.8 (t), 30.9 (d), 
31.0 (t), 34.0 (t), 39.3 (t), 47.5 (q), 52.3 (d), 55.6 (d), 55.8 (d), 
58.7 (q), 59.8 (q), 60.4 (s), 74.7 (t), 75.1 (d), 78.0 (d), 101.4 (t), 
101.8 (d), 102.0 (d), 122.1 (d), 124.6 (d), 127.5 (d), 127.9 (d), 
128.2 (d), 134.8 (s), 136.4 (s), 137.8 (s), 142.2 (s), 142.3 (s), 149.4 
(s), 152.8 (s), 178.3 (s); HRMS calcd for C42H52O10S2 780.968; 
the parent peak was not observed. Immediate fragmentation 
occurs between C3 and C6 (Figure 1). This results in the masses 
of 508.41 and 272.11: MS (rel intensity) 569 (0.14), 508 (2), 
272 (6), 269 (14), 250 (8), 196 (6), 179 (4), 165 (9), 163 (5),106 
(7), 91 (100). As a side product (11%) in this synthesis, 




To a stirred solution of 10 (190 mg, 0.273 mmol) in acetonitrile/ 
acetone/water, volume ratio 6:3:2.2 at room temperature, 
HgCl2 (289 mg, 0.612 mmol) and CaCO3 (114 mg, 1.139 mmol) 
were added. Reaction was followed on TLC (diethyl ether/ 
hexane, 2:1) and was complete after about 30 min. Subse-
quently, the reaction mixture was filtered and extracted with 
dichloromethane (50 mL). The organic layer was washed with 
water (2 × 30 mL) and brine (30 mL). Column chromatography 
with diethyl ether/hexane (3:2) yielded compound 13, 89 mg 
(0.147 mmol, 67%), as a colorless oil, which colorizes upon 
standing. This compound had to be repurified (column chro-
matography; diethyl ether/hexane, 3:2) before it could be used in 
cytotoxicity experiments: 1H NMR (CDCl3) δ 0.65-1.50 (m, 16 
H, menthyl), 1.70-2.3 (m, 2 H, CH-menthyl), 2.4-2.8 (m, 1 H, 
C8-H), 2.9-3.1 (m, 1 H, OCH-menthyl), 3.64 (s, 6 H, OCH3), 
3.75 (s, 3 H, OCH3), 3.8-3.9 (br, 1 H, ArCHOHR), 3.8 (br, 1 H, 
C8´-H), 4.05 (s, 3 H, OCH3), 4.65-4.80 (br, 1 H, CH-Omenthyl), 
5.99 (d, 2 H, 2J = 7 Hz, OCH2O), 6.25 (s, 2 H, Ar-H), 6.41 (d, 1 
H, 3JAB = 8.5 Hz, Ar-H), 7.08 (d, 2 H, 3JAB = 8.5 Hz, Ar-H); 13C 
NMR (CDCl3) δ 14.1 (d), 15.5 (q), 21.0 (q), 22.1 (d), 22.8 (t), 
24.0 (t), 25.7 (q), 26.9 (t), 27.6 (t), 31.2 (d), 34.2 (t), 47.6 (q), 
52.5 (d), 55.7 (d), 58.8 (q), 60.7 (q), 75.2 (d), 78.2 (d), 101.1 (d), 
101.5 (t), 102.1 (d), 124.7 (d), 135.0 (s), 137.4 (s), 139.4 (s), 
142.1 (s), 143.0 (s), 149.6 (s), 152.7 (s), 178.4 (s), 198.1 (s); 
HRMS 614.273, calcd for C33H42O11 614.273; MS (rel intensity) 
614 (M+, 9), 278 (14), 250 (8), 234 (5), 207 (5), 197 (11), 196 




dihydro-2(3H)-furanone (14).  At -12 °C, vinyl ethyl ether 
(0.50 mL, 0.377 g, 5.2 mmol) was added to a stirred solution of 
10 (276 mg, 0.393 mmol) and toluenesulfonic acid (0.1 g, 
catalytic amount) in dry THF (8.5 mL). After 1 h the reaction 
mixture was neutralized to pH 7.0 with 0.05 N KOH in absolute 
EtOH. The reaction mixture was diluted with diethyl ether (50 
mL) and washed with an aqueous KOH solution of pH 8 (30 
mL). The solvent was removed under a vacuum which was 
followed by flash chromatography with dichloro-
methane/hexane/triethylamine (16:1:0.01) to remove some 
impurities (Rf 14 = 0). Flash chromatography with diethyl 
ether/triethylamine (1:0.001) yielded 14, 274 mg (0.354 mmol, 
90%), as a white foam that became an oil upon standing: 1H 
NMR (CDCl3) δ 0.6-1.95 (m, 21 H, menthyl and CH3-
ethoxyethyl), 1.46 (d, 3 H, 3J = 5.9 Hz, CH3-ethoxyethyl), 1.99 
(t, 2 H, 3J = 6.7 and 7.3 Hz, CH2-dithiane), 2.72 (t, 2 H, 3J = 
7.8 Hz, CH2-dithiane), 2.8-2.9 (m, 1 H, C8-H), 3.02 (t, 2 H, 3J = 
7.1 Hz, CH2-dithiane), 3.40 (q, 2 H, 3J = 7.1 Hz, CH2-
ethoxyethyl), 3.5-3.6 (m, 1 H, OCH-menthyl), 3.6-3.8 (m, 1 
H, C8´-H), 3.9-4.0 (br, 1 H, ArCHOR, 3.87 (s, 6 H, OCH3), 
3.88 (s, 3 H, OCH3), 3.99 (q, 1 H, 3J = 26 Hz, CH-ethoxyethyl), 
3.99 (s, 3 H, OCH3), 4.1-4.3 (m, 1 H, OCH-Omenthyl), 5.95 (s, 
2H, OCH2O), 6.50 (d, 1 H, 3J = 8.3 Hz, Ar-H), 7.19 (s, 2H, Ar-
H). 7.34 (d, 1 H, 3J = 8.6 Hz, Ar-H); 13C NMR (CDCl3) δ 14.8 
(q), 15.3 (q), 15.4 (q), 19.8 (q), 21.1 (d), 22.1 (t), 22.6 (t), 24.1 
(q), 25.2 (t), 25.5 (t), 31.2 (d), 34.2 (t), 39.7 (t), 47.7 (d), 49.0 
(q), 52.9 (d), 55.8 (q), 58.8 (t), 59.2 (d), 60.7 (q), 61.1 (s), 76.5 
(d), 77.7 (d), 80.0 (d), 97.0 (d), 101.2 (t), 101.8 (d), 124.8 (d), 
125.0 (d), 134.5 (s), 137.1 (s), 139.5 (s), 142.4 (s), 149.4 (s), 
152.7  (s),  175.0  (s);   HRMS  776.326,  calcd  for  C40H56O11S2 
776.326; MS (rel intensity) 776 (M+, 0.7), 704 (4), 508 (8), 418




none (15).  The same procedure on the same scale was used as
that for compound 13; compound 14 was used as starting
material, and 1% triethylamine was added to the eluent for
chromatography. Compound 15, 150 mg (0.219 mmol, 80%),
was obtained as a colorless oil: 1H NMR (CDCl3) δ 0.6-2.3 (m,
21 H, menthyl and CH3-ethoxyethyl), 2.4-2.8 (m, 1 H, C8-H),
3.2-4.0 (m, 4 H, OCH-menthyl, C8´-H, CH2-ethoxyethyl), 3.76
(s, 6 H, OCH3), 3.85-3.95 (br, 1 H, ArCHOR), 3.89 (s, 3 H,
OCH3), 3.40 (s, 3 H, OCH3), 4.0-4.2 (br, 1 H, CH-Omenthyl),
6.00 (d, 2 H, 2J = 6.7 Hz, OCH2O), 6.25 (s, 2 H, Ar-H), 6.41 (d,
1 H, 3J = 8.7 Hz, Ar-H), 7.08 (d, 1 H, 3J = 7.9 Hz, Ar-H); 13C
NMR (CDCl3) δ 15.0 (q), 15.4 (q), 15.5 (q), 19.7 (q), 21.1 (d),
22.2 (t), 22.6 (t), 24.1 (q), 25.2 (t), 25.5 (t), 31.2 (d), 47.7 (d),
49.0 (q), 52.8 (d), 55.8 (q), 58.8 (t), 59.2 (d), 60.7 (q), 76.5 (d),
77.7 (d), 80.0 (d), 97.1 (d), 101.1 (t), 101.8 (d), 124.9 (d),
125.0 (d), 134.5 (s), 137.1 (s), 139.5 (s), 142.5 (s), 149.4 (s),
152.7 (s), 175.1 (s), 197.1 (s); HRMS 686.377, calcd for
C37H50O12 686.377; MS (rel intensity) 686 (M+, 0.62), 278 (14),
250 (8), 234 (5), 207 (5), 197 (11), 196 (44), 195 (6), 181 (20),
179 (11), 178 (100). 
(4R,5R)-4-[[3-Methoxy-1,2-(methylenedioxy)phenyl](1,3-
propylenedithio)methyl]-5-(l-menthyloxy)dihydro-2(4H)-
furanone (24).  The lithium enolate solution was poured into
100 mL of concentrated ammonium chloride solution and
extracted with diethyl ether (3 × 150 mL). Subsequently, the
organic layer was washed with 1 N HCl (2 × 50 mL), water
(100 mL), and brine (100 mL) and dried over magnesium
sulfate. The solvent was removed under reduced pressure.
Column chromatography with diethyl ether/hexane (1:2) (Rf 24
= 0) was followed by column chromatography with toluene/
ether (20:1) and yielded 24, 1.09 g (2.20 mmol, 53%), as a
colorless oil: [α]D +16.95° (c = 1); 1H NMR (CDCl3) δ 0.5-
2.05 (m, 19 H, menthyl and lactone), 2.6-3.3 (m, 6 H, dithiane),
3.55-3.65 (m, 1 H, lactone), 3.94 (s, 3 H, OCH3), 5.4 (br, 1 H,
OCHO), 6.07 (s, 2 H, OCH2O), 6.58 (d, 1 H, 3J = 3.14 Hz, Ar-
H), 7.47 (d, 1 H, 3J = 8.45 Hz, Ar-H); 13C NMR (CDCl3) δ 15.7
(q), 20.9 (q), 22.0 (q), 22.8 (t), 24.0 (t), 25.4 (d), 27.6 (t), 27.9
(t), 30.4 (t), 30.4 (d), 34.0 (t), 39.2 (t), 47.3 (d), 49.2 (d), 59.0
(s), 59.2 (d), 77.9 (d), 101.8 (t), 102.2 (d), 125.1 (s), 125.3 (d),
139.7 (s), 142.4 (s), 149.5 (s), 176.0 (s). 
(4R)-4-[[3-Methoxy-1,2-(methylenedioxy)phenyl](1,3-
propylenedithio)methyl]dihydro-2(5H)-furanone (25). To
a stirred solution of 24 (3.53 g, 7.11 mmol) in EtOH (absolute)
was added sodium borohydride (2.02 g, 53.5 mmol). Subse-
quently, KOH (0.81 g, 14.4 mmol) was added at once, and
stirring was continued for 1 h. The reaction mixture was
acidified to pH 4.0 with 1 N HCl and extracted with diethyl
ether. Compound 4 was the side product of this reaction, and
we were not able to find a successful purification method. Only
a small amount of 25 was isolated ( <1%): 1H NMR (CDCl3) δ
1.75-2.0 (m, 2 H, lactone), 2.42-2.53 (q, 1 H, 3J = 3.5 Hz,
lactone), 2.68-3.0 (m, 4 H, dithiane), 3.90 (s, 3 H, OCH3), 4.1-
4.5 (m, 2 H, lactone), 5.96 (s, 2 H, OCH2O), 6.52 (d, 1 H, 3JAB
= 8 Hz, Ar-H), 7.45 (d, 1 H, 3JAB = 8 Hz, Ar-H); 13C (CDCl3) δ
24.7 (t), 27.2 (t), 30.22 (t), 32.1 (s), 48.1 (d), 59.4 (q), 69.0 (t),
101.8 (t), 102.0 (d), 125.1 (d), 125.4 (s), 139.3 (s), 141.9 (s),
149.2 (s), 176.5 (s); HRMS 354.60, calcd for C16H18O5S2
354.60; MS (rel intensity) 354 (M+, 8), 271 (10), 270 (16), 269
(100), 251 (17), 233 (11), 221 (12), 195 (16). 
Deoxypodophyllotoxin (23).  Podophyllotoxin (1.3 g, 3.05
mmol) was dissolved in 70 mL of acetic acid, and 1.0 g of
palladium (10%) on carbon was added. Podophyllotoxin was
reduced under an atmosphere of hydrogen at 95 °C during 48 h
with stirring. Subsequently the reaction mixture was filtered,
and ca. 100 mL of diethyl ether was added to the clear solution.
The acetic acid was removed by washing the ether layer with a
large amount of water (1.5 L). The ether layer was
concentrated to ca. 10 mL and submitted to flash chro-
matography with diethyl ether as eluent. Removal of the
solvent yielded a slightly yellow residue (1.0 g, 81%) consisting
of pure deoxypodophyllotoxin: [α]D -116.4° (c = 0.80); 1H NMR 
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(CDCl3) δ 6.67 (s, 1 H, C5-H), 6.52 (s, 1 H, C2-H), 6.35 (s, 2 H, 
H-2´ and H-6´), 5.95 (d, 1 H, J = 1.3 Hz, C10-H), 5.93 (d, 1 H, J 
= 1.3 Hz, C10-H), 4.6 (m, 1 H, C7-H), 4.5 (m, 1 H, C9-H), 3.9 
(m, 1 H, C9-H), 3.81 (s, 3 H, 4´OCH3), 3.75 (s, 6 H, 3´ and 
5´OCH3), 3.08 (m, 1 H, C7´-H), 2.7-2.8 (m, 3 H, C8-H, C8´-H, 
and C7´-H); 13C NMR (CDCl3) δ 175.0 (s), 152.4 (s), 146.9 (s), 
146.6 (d), 136.8 (s), 136.3 (s), 130.5 (s), 128.3 (s), 110.3 (s), 
108.4 (d), 108.2 (s), 101.1 (t), 72.0 (t), 60.6 (d), 56.1 (q), 47.3 
(d), 43.7 (d), 32.9 (d), 32.7 (d); MS (rel intensity) 398 (M+, 100), 
230 (23), 199 (16), 185 (67), 181 (100), 173 (84), 168 (43), 153 
(40); MS (PICI, NH3) m/e 399 (M + 1), 416 (M + NH4+). 
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